Upstream Bio Net Income
| UPB Stock | 27.81 1.69 6.47% |
As of the 10th of February, Upstream Bio has the Risk Adjusted Performance of 0.0374, coefficient of variation of 2748.81, and Semi Deviation of 4.19. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Upstream Bio, as well as the relationship between them.
Upstream Bio Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 372.6981 | Revenue | Earnings Share (6.40) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.5 M | -59.4 M | |
| Net Loss | -56.5 M | -59.4 M | |
| Net Loss | (1.41) | (1.48) |
Upstream | Net Income | Build AI portfolio with Upstream Stock |
Analyzing Upstream Bio's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Upstream Bio's current valuation and future prospects.
Latest Upstream Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Upstream Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Upstream Bio financial statement analysis. It represents the amount of money remaining after all of Upstream Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Upstream Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Upstream Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (62.81 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Upstream Net Income Regression Statistics
| Arithmetic Mean | (29,970,828) | |
| Coefficient Of Variation | (47.33) | |
| Mean Deviation | 10,443,598 | |
| Median | (23,868,000) | |
| Standard Deviation | 14,185,608 | |
| Sample Variance | 201.2T | |
| Range | 42.3M | |
| R-Value | (0.64) | |
| Mean Square Error | 127.7T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | (1,787,853) | |
| Total Sum of Squares | 3219.7T |
Upstream Net Income History
Other Fundumenentals of Upstream Bio
Upstream Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Upstream Bio is extremely important. It helps to project a fair market value of Upstream Stock properly, considering its historical fundamentals such as Net Income. Since Upstream Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Upstream Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Upstream Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Upstream Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Upstream Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Upstream Bio.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Upstream Bio on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Upstream Bio or generate 0.0% return on investment in Upstream Bio over 90 days. Upstream Bio is related to or competes with Zenas BioPharma, Intellia Therapeutics, Wave Life, Relay Therapeutics, Pharvaris, Syndax Pharmaceuticals, and Novavax. Upstream Bio is entity of United States. It is traded as Stock on NASDAQ exchange. More
Upstream Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Upstream Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Upstream Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.48 | |||
| Information Ratio | 0.014 | |||
| Maximum Drawdown | 24.37 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 7.84 |
Upstream Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Upstream Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Upstream Bio's standard deviation. In reality, there are many statistical measures that can use Upstream Bio historical prices to predict the future Upstream Bio's volatility.| Risk Adjusted Performance | 0.0374 | |||
| Jensen Alpha | 0.1418 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0137 | |||
| Treynor Ratio | 1.63 |
Upstream Bio February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0374 | |||
| Market Risk Adjusted Performance | 1.64 | |||
| Mean Deviation | 3.23 | |||
| Semi Deviation | 4.19 | |||
| Downside Deviation | 4.48 | |||
| Coefficient Of Variation | 2748.81 | |||
| Standard Deviation | 4.39 | |||
| Variance | 19.31 | |||
| Information Ratio | 0.014 | |||
| Jensen Alpha | 0.1418 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0137 | |||
| Treynor Ratio | 1.63 | |||
| Maximum Drawdown | 24.37 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 7.84 | |||
| Downside Variance | 20.05 | |||
| Semi Variance | 17.53 | |||
| Expected Short fall | (3.38) | |||
| Skewness | (0.22) | |||
| Kurtosis | 1.26 |
Upstream Bio Backtested Returns
Upstream Bio appears to be not too volatile, given 3 months investment horizon. Upstream Bio owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0798, which indicates the firm had a 0.0798 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Upstream Bio, which you can use to evaluate the volatility of the company. Please review Upstream Bio's Risk Adjusted Performance of 0.0374, coefficient of variation of 2748.81, and Semi Deviation of 4.19 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Upstream Bio holds a performance score of 6. The entity has a beta of 0.092, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Upstream Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Upstream Bio is expected to be smaller as well. Please check Upstream Bio's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Upstream Bio's existing price patterns will revert.
Auto-correlation | 0.24 |
Weak predictability
Upstream Bio has weak predictability. Overlapping area represents the amount of predictability between Upstream Bio time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Upstream Bio price movement. The serial correlation of 0.24 indicates that over 24.0% of current Upstream Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 4.65 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Upstream Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Upstream Bio reported net income of (62.81 Million). This is 118.4% lower than that of the Biotechnology sector and 189.66% lower than that of the Health Care industry. The net income for all United States stocks is 111.0% higher than that of the company.
Upstream Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Upstream Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Upstream Bio could also be used in its relative valuation, which is a method of valuing Upstream Bio by comparing valuation metrics of similar companies.Upstream Bio is currently under evaluation in net income category among its peers.
Upstream Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Upstream Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Upstream Bio's managers, analysts, and investors.Environmental | Governance | Social |
Upstream Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (55.39) % | ||||
| Current Valuation | 1.04 B | ||||
| Shares Outstanding | 54.04 M | ||||
| Shares Owned By Insiders | 14.77 % | ||||
| Shares Owned By Institutions | 93.30 % | ||||
| Number Of Shares Shorted | 3.45 M | ||||
| Price To Book | 3.74 X | ||||
| Price To Sales | 505.83 X | ||||
| Revenue | 2.37 M | ||||
| Gross Profit | 2.8 M | ||||
| EBITDA | (77.67 M) | ||||
| Net Income | (62.81 M) | ||||
| Total Debt | 1.83 M | ||||
| Book Value Per Share | 7.01 X | ||||
| Cash Flow From Operations | (59.17 M) | ||||
| Short Ratio | 7.89 X | ||||
| Earnings Per Share | (6.40) X | ||||
| Target Price | 49.75 | ||||
| Number Of Employees | 52 | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 481.72 M | ||||
| Retained Earnings | (190.78 M) | ||||
| Working Capital | 468.42 M | ||||
| Net Asset | 481.72 M |
About Upstream Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Upstream Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio Stock:Check out For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.